Tufts Medical Center's Center for the Evaluation of Value and Risk in Health (CEVR) is pleased to announce the winner of our third annual Cost-Effectiveness Analysis (CEA) Paper of the Year Award.
The winner is…
Nosyk B, Zang X, Krebs E, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Golden M, Marshall BDL, Mehta SH, Metsch LR, Pandya A, Schackman BR, Shoptaw S, Strathdee SA; Localized HIV Modeling Study Group. Ending the HIV epidemic in the USA: an economic modelling study in six cities. Lancet HIV. 2020 Jul;7(7):e491-e503. doi: 10.1016/S2352-3018(20)30033-3.
With a team of esteemed researchers from across Canada and the United States, a lead author, Dr. Bohdan Nosyk, an associate professor in the Faculty of Health Sciences at Simon Fraser University in Burnaby, BC, Canada and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research, conducted an economic modeling study to examine cost-effectiveness of combination strategies among of 16 evidence-based HIV-related interventions (HIV prevention, testing, treatment, engagement, and re-engagement) across six cities in the US. The study found substantial public health and economic value of delivering optimal combination strategies, yet highlighted some challenges (e.g., social and structural barriers to HIV care) to reach national targets of ending the HIV epidemic initiative by 2030.
Dr. Nosyk’s paper was chosen from a competitive pool of 25 high-quality submissions for its exemplary methodological quality and timeliness. Each paper underwent a blinded review by CEVR directors and faculty members, who evaluated the submissions for methodological quality, timeliness, and potential influence on policy or clinical decision-making. The top three papers with the highest faculty ratings were then reviewed by CEVR’s CEA Registry Scientific Advisory Board using the same criteria.
The two other finalists included a cost-effectiveness analysis of intranasal naloxone distribution to high-risk prescription opioid (RxO) users, and follow-up examinations and secondary isoniazid preventive therapy for those undergoing tuberculosis treatment in South Africa.
Runners-up
- Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value Health. 2020 Apr;23(4):451-460. doi: 10.1016/j.jval.2019.12.002.
- Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. Lancet Glob Health. 2020 Sep;8(9):e1223-e1233. doi: 10.1016/S2214-109X(20)30227-8
CEVR will announce a call for 2021 submissions in the fall of this year.